IFCC Network for Standardization of HbA1c

Welcome to the website of the IFCC Network for Standardization of HbA1c

The purpose of the IFCC Network for Standardization of HbA1c is to standardize HbA1c test results of routine methods to the IFCC Reference Measurement Procedure.

Diabetes Mellitus has become a worldwide epidemic, affecting 400 million people. Effective and efficient monitoring of diabetic control and diagnosis requires a good marker for estimation of the average blood glucose over a longer period. HbA1c meets this requirement for such a reliable compass to guide therapy.
For optimal clinical use (e.g. uniform clinical guidelines, uniform reference values, comparison of scientific studies) equivalence of results is desirable: results of any laboratory anywhere in the world and irrespective the routine method used, should be the same. This requires standardization. The IFCC Reference Measurement Procedure for HbA1c is the analytical anchor for the worldwide standardization of all routine HbA1c assays.
General information

NEWS EurA1c 2022

The EurA1c trial, organized yearly, investigates the performance of HbA1c assays across countries and manufacturers. The trial has Eurocentric roots but in the meantime also non-European countries are participating. In 2021 the sixth trial was organised where more than 4000 laboratories in 21 countries participated. The 2022 EurA1c trial will be running from October 2022 to April 2023. Reports from the trials are available at the website under general information. Results of the first EurA1c trial are published in Clin Chem 2018;64:1183-92